EPRX FY2025 EPS Forecast Lowered by Cantor Fitzgerald

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) – Stock analysts at Cantor Fitzgerald lowered their FY2025 earnings estimates for Eupraxia Pharmaceuticals in a report issued on Thursday, August 14th. Cantor Fitzgerald analyst K. Kluska now anticipates that the company will earn ($0.70) per share for the year, down from their prior forecast of ($0.63). Cantor Fitzgerald currently has a “Overweight” rating and a $11.00 price objective on the stock. The consensus estimate for Eupraxia Pharmaceuticals’ current full-year earnings is ($0.67) per share. Cantor Fitzgerald also issued estimates for Eupraxia Pharmaceuticals’ FY2026 earnings at ($0.67) EPS.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05).

EPRX has been the topic of several other research reports. HC Wainwright initiated coverage on shares of Eupraxia Pharmaceuticals in a report on Thursday, June 26th. They issued a “buy” rating and a $12.00 target price on the stock. Canaccord Genuity Group initiated coverage on shares of Eupraxia Pharmaceuticals in a report on Monday, June 16th. They issued a “speculative buy” rating on the stock. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Eupraxia Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $11.00.

Eupraxia Pharmaceuticals Stock Performance

EPRX stock opened at $5.32 on Monday. Eupraxia Pharmaceuticals has a one year low of $2.20 and a one year high of $6.20. The company’s fifty day moving average price is $5.07 and its 200-day moving average price is $4.14. The company has a market capitalization of $191.31 million, a PE ratio of -6.26 and a beta of 1.50.

Institutional Investors Weigh In On Eupraxia Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the business. Scotia Capital Inc. raised its stake in Eupraxia Pharmaceuticals by 11.6% during the first quarter. Scotia Capital Inc. now owns 1,552,679 shares of the company’s stock valued at $5,072,000 after purchasing an additional 160,960 shares in the last quarter. Royal Bank of Canada raised its stake in Eupraxia Pharmaceuticals by 21.1% during the first quarter. Royal Bank of Canada now owns 342,828 shares of the company’s stock valued at $1,125,000 after purchasing an additional 59,683 shares in the last quarter. Bank of Montreal Can raised its stake in Eupraxia Pharmaceuticals by 15.2% during the fourth quarter. Bank of Montreal Can now owns 56,750 shares of the company’s stock valued at $178,000 after purchasing an additional 7,500 shares in the last quarter. Ingalls & Snyder LLC purchased a new stake in Eupraxia Pharmaceuticals during the second quarter valued at $214,000. Finally, JPMorgan Chase & Co. raised its stake in Eupraxia Pharmaceuticals by 593.2% during the second quarter. JPMorgan Chase & Co. now owns 18,717 shares of the company’s stock valued at $108,000 after purchasing an additional 16,017 shares in the last quarter.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.